- Home
- SD vs CRVS Comparison
SD vs CRVS Comparison
Compare SD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- CRVS
- Stock Information
- Founded
- SD 2006
- CRVS 2014
- Country
- SD United States
- CRVS United States
- Employees
- SD N/A
- CRVS N/A
- Industry
- SD Oil & Gas Production
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- CRVS Health Care
- Exchange
- SD Nasdaq
- CRVS Nasdaq
- Market Cap
- SD 429.3M
- CRVS 459.0M
- IPO Year
- SD 2007
- CRVS 2016
- Fundamental
- Price
- SD $11.73
- CRVS $5.79
- Analyst Decision
- SD
- CRVS Strong Buy
- Analyst Count
- SD 0
- CRVS 4
- Target Price
- SD N/A
- CRVS $15.00
- AVG Volume (30 Days)
- SD 249.4K
- CRVS 547.2K
- Earning Date
- SD 11-05-2025
- CRVS 11-11-2025
- Dividend Yield
- SD 4.08%
- CRVS N/A
- EPS Growth
- SD 86.17
- CRVS N/A
- EPS
- SD 2.03
- CRVS N/A
- Revenue
- SD $146,165,000.00
- CRVS N/A
- Revenue This Year
- SD $30.71
- CRVS N/A
- Revenue Next Year
- SD $10.06
- CRVS N/A
- P/E Ratio
- SD $5.79
- CRVS N/A
- Revenue Growth
- SD 13.89
- CRVS N/A
- 52 Week Low
- SD $8.81
- CRVS $2.54
- 52 Week High
- SD $13.19
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- SD 57.03
- CRVS 56.88
- Support Level
- SD $11.33
- CRVS $5.64
- Resistance Level
- SD $11.65
- CRVS $6.09
- Average True Range (ATR)
- SD 0.28
- CRVS 0.34
- MACD
- SD -0.03
- CRVS -0.05
- Stochastic Oscillator
- SD 48.48
- CRVS 50.00
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).